Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma

Key Points

The use of platinum-based chemotherapy did not improve survival rates among patients with metastatic pancreatic ductal adenocarcinoma.
Only modest increases in treatment-related toxicities were associated with platinum regimens compared to non-platinum options.
This observational analysis highlights the need for careful evaluation of chemotherapy effectiveness in heavily pretreated patients.
Further research may be necessary to optimize treatment options for this patient population.

Abstract

This study showed that a platinum-based third-line chemotherapy regimen for patients with metastatic PDAC did not confer a significant survival advantage over non-platinum-based regimens. Platinum-based regimens are associated with modestly increased treatment-related toxicities, thus potentially limiting their tolerability in these heavily pretreated patients.

Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma

Key Points

Abstract

Cite This Study

Also Consider

Also Consider